R & D

Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

 This material is intended to notify the press release issued on April 8 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.